D1000 Varejo Farma Participacoes SA

As of March 31, 2026, D1000 Varejo Farma Participacoes SA carries a market capitalization of 361.30M, placing it among publicly traded companies globally. Its enterprise value stands at 873.34M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

D1000 Varejo Farma Participacoes SA's next confirmed earnings release is scheduled for November 11, 2026.

As of March 31, 2026, D1000 Varejo Farma Participacoes SA has 50.60M shares outstanding.

As of March 31, 2026, D1000 Varejo Farma Participacoes SA trades at a trailing price-to-earnings ratio of 15.09. The price-to-sales ratio is 0.13, and the price-to-book ratio stands at 0.39.

As of March 31, 2026, D1000 Varejo Farma Participacoes SA trades at an EV/EBITDA multiple of 3.66 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.75 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 873.34M versus a market cap of 361.30M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, D1000 Varejo Farma Participacoes SA maintains a current ratio of 1.06, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 58.11, indicating elevated leverage, while an interest coverage ratio of 3.22 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, D1000 Varejo Farma Participacoes SA posted a return on equity (ROE) of 2.64, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 1.26, measuring how efficiently the asset base is converted into earnings. The company generates approximately 780,212.10 in revenue per employee across its workforce of 3,536.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.85 indicates how many times D1000 Varejo Farma Participacoes SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, D1000 Varejo Farma Participacoes SA recorded an income tax benefit of -3.72M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 20.23M, leaving 23.95M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, D1000 Varejo Farma Participacoes SA's stock has gained approximately 40.30% over the past 52 weeks. The 50-day moving average sits at 6.29, while the 200-day moving average is 6.62.

Over the twelve months ended March 31, 2026, D1000 Varejo Farma Participacoes SA generated 2.76B in revenue and converted that into 23.95M in net income, yielding earnings per share of 0.47. EBITDA reached 238.43M, while operating income came in at 99.77M.

As of March 31, 2026, D1000 Varejo Farma Participacoes SA holds 22.99M in cash and equivalents against 535.03M in total debt, resulting in a net debt position of 86.97M. Total book value stands at 920.79M, with working capital of 33.29M providing operational flexibility.

D1000 Varejo Farma Participacoes SA produced 170.45M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -44.75M in capital expenditures, free cash flow totaled 125.70M - equivalent to 2.48 per share.

Over the twelve months ended March 31, 2026, D1000 Varejo Farma Participacoes SA posted a gross margin of 28.80, reflecting its pricing power and cost economics. The operating margin of 3.62 and net profit margin of 0.87 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 34.79, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 23.63, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to D1000 Varejo Farma Participacoes SA shareholders.

As of March 31, 2026, D1000 Varejo Farma Participacoes SA has an Altman Z-Score of 2.40, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.